title: A dosimetric evaluation of knowledge-based VMAT planning with simultaneous integrated boosting for rectal cancer patients.
abstract: RapidPlan, a commercial knowledge-based optimizer, has been tested on head and neck, lung, esophageal, breast, liver, and prostate cancer patients. To appraise its performance on VMAT planning with simultaneous integrated boosting (SIB) for rectal cancer, this study configured a DVH (dose-volume histogram) estimation model consisting 80 best-effort manual cases of this type. Using the model-generated objectives, the MLC (multileaf collimator) sequences of other 70 clinically approved plans were reoptimized, while the remaining parameters, such as field geometry and photon energy, were maintained. Dosimetric outcomes were assessed by comparing homogeneity index (HI), conformal index (CI), hot spots (volumes receiving over 107% of the prescribed dose, V107%), mean dose and dose to the 50% volume of femoral head (Dmean_FH and D50%_FH), and urinary bladder (Dmean_UB and D50%_UB), and the mean DVH plotting. Paired samples t-test or Wilcoxon signed-rank test suggested that comparable CI were achieved by RapidPlan (0.99± 0.04 for PTVboost, and 1.03 ± 0.02 for PTV) and original plans (1.00 ± 0.05 for PTVboost and 1.03 ± 0.02 for PTV), respectively (p > 0.05). Slightly improved HI of planning target volume (PTVboost) and PTV were observed in the RapidPlan cases (0.05 ± 0.01 for PTVboost, and 0.26 ± 0.01 for PTV) than the original plans (0.06 ± 0.01 for PTVboost and 0.26 ± 0.01 for PTV), p < 0.05. More cases with positive V107% were found in the original (18 plans) than the RapidPlan group (none). RapidPlan significantly reduced the D50%_FH (by 1.53 Gy / 9.86% from 15.52 ± 2.17 to 13.99± 1.16 Gy), Dmean_FH (by 1.29 Gy / 7.78% from 16.59± 2.07 to 15.30 ± 0.70 G), D50%_UB (by 4.93 Gy / 17.50% from 28.17 ± 3.07 to 23.24± 2.13 Gy), and Dmean_UB (by 3.94Gy / 13.43% from 29.34 ± 2.34 to 25.40 ± 1.36 Gy), respectively. The more concentrated distribution of RapidPlan data points indicated an enhanced consis-tency of plan quality.
authors.affiliation: Peking University Cancer Hospital & Institute. 13552661030@139.com.
authors.forename: Hao
authors.initials: H
authors.lastname: Wu
authors.forename: Fan
authors.initials: F
authors.lastname: Jiang
authors.forename: Haizhen
authors.initials: H
authors.lastname: Yue
authors.forename: Sha
authors.initials: S
authors.lastname: Li
authors.forename: Yibao
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D006801:Humans; D051188:Knowledge Bases; D058958:Organs at Risk / Q000528:radiation effects*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods* / Q000592:standards*; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods*; D012004:Rectal Neoplasms / Q000532:radiotherapy*